Novavax Says COVID-19 Vaccine 90 Percent Effective in U.S., Mexico Trials

Maryland-based biotechnology company Novavax has produced its own COVID-19 vaccine as more variants continue to circulate the globe. The company says the vaccine has shown to be 90 percent effective during trials in the U.S. and Mexico. Logistically, distributing the vaccine is easier to store and transport for more difficult to reach parts of the world. Novavax will seek emergency use around September when they expect to be able to produce 100 million doses per month.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.